St13 protects against disordered acinar cell arachidonic acid pathway in chronic pancreatitis
Brief intro:
- Author: Rong-chang Cao, Wan-jun Yang, Wang Xiao, Lei Zhou, Jie-hui Tan, Meng Wang, Zhi-tao Zhou, Huo-ji Chen, Jia Xu, Xue-mei Chen, Yang-chen Jin, Jia-yu Lin, Jun-ling Zeng, Shu-ji Li, Min Luo, Guo-dong Hu, Jin Jin, Xiao-bing Yang, Da Huo, Jie Zhou, and Guo-wei Zhang
- Journal: J Transl Med
- Doi: https://www.doi.org/10.1186/s12967-022-03413-8
- Publication Date: 2022-05-13
Products/Services used in the paper
Quotation shows PackGene:All adeno-associated virus (PackGene Biotech, China) used are listed in Additional file 4: Fig. S4.
Research Field:pancreas
AAV Serotype:AAV
Abstract
Early diagnosis and treatment of chronic pancreatitis (CP) are limited. In this study, St13, a co-chaperone protein, was investigated whether it constituted a novel regulatory target in CP. Meanwhile, we evaluated the value of micro-PET/CT in the early diagnosis of CP.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
